Qiagen NV (QIA)

44.155
+0.700(+1.61%)
  • Volume:
    518,622
  • Bid/Ask:
    43.980/44.330
  • Day's Range:
    43.295 - 44.155
  • Type:Equity
  • Market:Germany
  • ISIN:NL0012169213
  • WKN:A2DKCH

QIA Overview

Prev. Close
44.155
Day's Range
43.295-44.155
Revenue
1.71B
Open
43.725
52 wk Range
36-46.95
EPS
1.58
Volume
518,622
Market Cap
10.06B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
490,165
P/E Ratio
24.98
Beta
0.1
1-Year Change
-35.12%
Shares Outstanding
227,752,000
Next Earnings Date
Nov 03, 2021
What is your sentiment on Qiagen NV?
or
Market is currently closed. Voting is open during market hours.

Qiagen NV News

Qiagen NV Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Qiagen NV Company Profile

Qiagen NV Company Profile

Employees
5750
Market
Germany

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Read More
  • this one will keep riding as long as there is covid19
    2
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.